@article {Irazu862作者={我{\ ~ n} igo Oyarzun Irazu和安东尼奥·卡布瑞拉色差和丹尼尔集市{\ \我}游泳C {\ ' o} ndor和克丽古铁雷斯和伊万卡巴雷若哈·阿奎莱拉和胡安•曼努埃尔•加西亚桑切斯Alejandra Collia费尔南德斯和约瑟Dalmau弗朗西斯克格劳和胡安·卡洛斯Garc{\ \我}a-Monc {\ ' o}}, title = {Oligosymptomatic anti-GABA受体脑炎:新的诊断和治疗的挑战(p1 - 1.虚拟)},体积={98},数量={18补充},elocation-id ={862} ={2022},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述一个Oligosymptomatic anti-GABA受体脑炎。首页背景:对GABA受体的抗体是与各种各样的严重的神经系统功能,形成癫痫持续状态进步的脑病。百分之六十的病人港肿瘤,主要是胸腺瘤。通常脑MRI显示弥漫性cortico-subcortical hyperintense(天赋)病变。设计/方法:一个60年的老女人恰加斯病的历史和卵巢囊肿表现为头痛和脉动hemisensory综合症也包括面对过去5天。结果:脑部MRI显示幕上的几个cortico-subcortical病变,波动消失,其中一些,新病灶的出现。一些病变显示轻微的钆增强。脑电图显示轻度刺激性的右额颞区域的变化。脑脊液显示10淋巴细胞/ mm3和一些寡克隆条带模式II。广泛的检查对肿瘤、自身免疫和感染性条件是负面的。免疫组织化学研究血清和CSF对啮齿动物的大脑显示GABA受体抗体的存在。她自发恢复,但针对结果,如果静脉注射免疫球蛋白治疗5天课程。 Her evolution so far (1 year of follow-up) has been benign, without any further relapses.Conclusions: GABA A receptor encephalitis may also have a more benign presentation, and should be considered in the presence of consistent MRI findings. The therapeutic approach in these cases remains challenging.Disclosure: Dr. Oyarzun Irazu has nothing to disclose. Mr. Muras has nothing to disclose. Dr. C{\'o}ndor has nothing to disclose. Miss Gutierrez has nothing to disclose. Dr. Caballero has nothing to disclose. Mr. Aguilera has nothing to disclose. Dr. Garcia Sanchez has nothing to disclose. Mrs. Collia Fernandez has nothing to disclose. Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Lamson Dugan \& Murray LLP. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Department of Health, Government of Catalunya. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Graus has nothing to disclose. Dr. Garcia Monco Carra has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/98/18_Supplement/862}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }